| Baseline iron stores | Baseline Hgb | Mean change in Hgb | Funding source |
|---|---|---|---|
| TSAT%: 23 | 10.4 | For overall cohort (n = 4044) | Amgen |
| Ferritin: 134 | Median achieved Hgb 12.5 (change of 2.1) versus 10.6 (change of 0.1) | ||
| Ferritin (Hgb 13.5 group versus Hgb 11.3 group): 159.5 versus 193.5, P = 0.050. TSAT%: 22.1 versus 24.1, P = 0.043 | Hgb 13.5: 10.0 | Achieved mean Hgb was 12.6 in the target group with 13.5. Mean change in Hgb was 2.5 in the high target group versus 1.2 in the low target group | CHOIR funded by Ortho Biotech and Johnson & Johnson. This secondary analysis by NIH |
| Hgb 11.3: 10.0 | |||
| Ferritin (Hgb 13–15 group versus Hgb 10.5–11.5 group): 174.4 versus 189.4, TSAT%: 25% versus 38% | Baseline Hgb 11.6 in both groups | Achieved Hgb was 13.49 in group 1 versus 11.6 in group 2 | Roche/Neorecormon® (epoetin-beta) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.